Table 2 Patient and tumor characteristics of the study cohort stratified by neutrophil-to-lymphocyte ratio (NLR)
Patient Groups | P-Value | |||||||
|---|---|---|---|---|---|---|---|---|
Below 2.5 | Above 2.5 | |||||||
Count | Row N % | Median (IQR) | Count | Row N % | Median (IQR) | |||
Age | 47 | 41.6% | 69 (59, 75) | 66 | 58.4% | 77 (70, 83) | ||
Status | No Recurrence | 28 | 57.1% | 21 | 42.9% | 0.003 | ||
Recurrence | 19 | 29.7% | 45 | 70.3% | ||||
Sex | Female | 6 | 35.3% | 11 | 64.7% | 0.568 | ||
Male | 41 | 42.7% | 55 | 57.3% | ||||
Grade | 1 | 35 | 45.5% | 42 | 54.5% | 0.293 | ||
2 | 0 | 0.0% | 2 | 100.0% | ||||
3 | 12 | 35.3% | 22 | 64.7% | ||||
Stage | Ta | 40 | 48.8% | 42 | 51.2% | 0.012 | ||
T1 | 7 | 22.6% | 24 | 77.4% | ||||
CIS | No | 44 | 40.0% | 66 | 60.0% | 0.037 | ||
Yes | 3 | 100.0% | 0 | 0.0% | ||||
Number Of Tumors | Single Tumor | 14 | 40.0% | 21 | 60.0% | 0.635 | ||
2–7 Tumors | 26 | 40.0% | 39 | 60.0% | ||||
8 or More | 7 | 53.8% | 6 | 46.2% | ||||
Tumor Diameter | < 30 mm | 30 | 39.5% | 46 | 60.5% | 0.512 | ||
30 mm or mo re | 17 | 45.9% | 20 | 54.1% | ||||
Past TCC | No | 32 | 40.0% | 48 | 60.0% | 0.593 | ||
Yes | 15 | 45.5% | 18 | 54.5% | ||||
WBC | 47 | 41.6% | 7.58 (6.17, 8.6) | 66 | 58.4% | 8.91 (7.05, 10.5) | 0.007 | |
Treatment Type | No Treatment | 17 | 38.6% | 27 | 61.4% | 0.317 | ||
MMC | 11 | 34.4% | 21 | 65.6% | ||||
BCG | 19 | 51.4% | 18 | 48.6% | ||||